Agilent to Acquire Resolution Bioscience for $695M

 Agilent to Acquire Resolution Bioscience for $695M

Agilent to Acquire Resolution Bioscience for $695M

Shots:

  • Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021
  • The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally
  • The acquisition will bring together Resolution’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based CDx and global commercial and regulatory scale

Click here ­to­ read full press release/ article | Ref: Agilent | Image: Resolution Bio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post